Fresh off its Juluca approval, GlaxoSmithKline beefs up trials of long-acting HIV duo
admin 28th November 2017 Uncategorised 0GlaxoSmithKline’s ViiV only just won its first two-drug HIV approval, but it’s already bolstering its trial program to see just how convenient it can make a two-drug regimen.
More: Fresh off its Juluca approval, GlaxoSmithKline beefs up trials of long-acting HIV duo
Source: fierce